Yonsei Med J.  2015 Mar;56(2):433-439. 10.3349/ymj.2015.56.2.433.

Efficacy of Surfactant-TA, Calfactant and Poractant Alfa for Preterm Infants with Respiratory Distress Syndrome: A Retrospective Study

• Jeon GW
• Oh M
• Sin JB

• KMID: 2070021
• DOI: http://doi.org/10.3349/ymj.2015.56.2.433

Abstract

PURPOSE
To compare the efficacy of the new drug calfactant with the commonly used drugs surfactant-TA and poractant alfa.
MATERIALS AND METHODS
A total of 332 preterm infants at 24-31 weeks' gestation with respiratory distress syndrome (RDS) were enrolled and allocated to three groups according to the surfactant instilled; Group 1 (n=146, surfactant-TA), Group 2 (n=96, calfactant), and Group 3 (n=90, poractant alfa). The diagnosis of RDS and the decision to replace the pulmonary surfactant were left to the attending physician and based on patient severity determined by chest radiography and blood gas analysis. Data were collected and reviewed retrospectively using patient medical records.
RESULTS
Demographic factors including gestational age, birth weight, Apgar score, clinical risk index for babies II score, and maternal status before delivery were not different between the study groups. Instances of surfactant redosing and pulmonary air leaks, as well as duration of mechanical ventilation, were also not different. Rates of patent ductus arteriosus, intraventricular hemorrhage (> or =grade III), periventricular leukomalacia, high stage retinopathy of prematurity, necrotizing enterocolitis (> or =stage II), and mortality were also similar, as was duration of hospital stay. Cases of pulmonary hemorrhage and moderate to severe bronchopulmonary dysplasia were increased in Group 3.
CONCLUSION
Calfactant is equally as effective as surfactant-TA and poractant alfa. This was the first study comparing the efficacy of surfactant-TA, calfactant, and poractant alfa in a large number of preterm infants in Korea. Further randomized prospective studies on these surfactants are needed.

Keyword

Pulmonary surfactants; beractant; poractant alfa; calfactant; respiratory distress syndrome

MeSH Terms

Biological Products/administration & dosage/*therapeutic use
Birth Weight
Bronchopulmonary Dysplasia/drug therapy
Female
Gestational Age
Humans
Infant, Newborn
Infant, Premature
Male
Phospholipids/administration & dosage/*therapeutic use
Pulmonary Surfactants/administration & dosage/*therapeutic use
Republic of Korea
Respiration, Artificial
Respiratory Distress Syndrome, Newborn/*drug therapy
Retrospective Studies
Risk
Treatment Outcome
Ventilator Weaning
Biological Products
Phospholipids
Pulmonary Surfactants

Reference

1. Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T. Artificial surfactant therapy in hyaline-membrane disease. Lancet. 1980; 1:55–59.

2. Halliday HL. History of surfactant from 1980. Biol Neonate. 2005; 87:317–322.

3. Engle WA. American Academy of Pediatrics Committee on Fetus and Newborn. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics. 2008; 121:419–432.

4. Logan JW, Moya FR. Animal-derived surfactants for the treatment and prevention of neonatal respiratory distress syndrome: summary of clinical trials. Ther Clin Risk Manag. 2009; 5:251–260.

5. Obladen M. History of surfactant up to 1980. Biol Neonate. 2005; 87:308–316.

6. Moya F. Synthetic surfactants: where are we? Evidence from randomized, controlled clinical trials. J Perinatol. 2009; 29:Suppl 2. S23–S28.

7. Soll RF, Blanco F. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev. 2001; CD000144.

8. Jobe A. Respiratory distress syndrome--new therapeutic approaches to a complex pathophysiology. Adv Pediatr. 1983; 30:93–130.

9. Jobe AH. 50 Years ago in The Journal of Pediatrics: Respiratory distress syndrome of newborn infants: I. Diagnosis and incidence Miller H. J Pediatr 1962;61:2-8. Respiratory Distress Syndrome of Newborn Infants: II. Clinical Study of Pathogenesis Miller H. J Pediatr 1962;61:9-16. J Pediatr. 2012; 161:93.

10. Lubchenco LO, Hansman C, Dressler M, Boyd E. Intrauterine growth as estimated from Liveborn birth-weight data at 24 to 42 weeks of gestation. Pediatrics. 1963; 32:793–800.

11. Kinsella JP, Greenough A, Abman SH. Bronchopulmonary dysplasia. Lancet. 2006; 367:1421–1431.

12. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 1978; 92:529–534.

13. An international classification of retinopathy of prematurity. Pediatrics. 1984; 74:127–133.

14. Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am. 1986; 33:179–201.

15. Stoll BJ, Hansen NI, Adams-Chapman I, Fanaroff AA, Hintz SR, Vohr B, et al. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA. 2004; 292:2357–2365.

16. Rüdiger M, von Baehr A, Haupt R, Wauer RR, Rüstow B. Preterm infants with high polyunsaturated fatty acid and plasmalogen content in tracheal aspirates develop bronchopulmonary dysplasia less often. Crit Care Med. 2000; 28:1572–1577.

17. Ramanathan R. Animal-derived surfactants: where are we? The evidence from randomized, controlled clinical trials. J Perinatol. 2009; 29:Suppl 2. S38–S43.

18. Singh N, Hawley KL, Viswanathan K. Efficacy of porcine versus bovine surfactants for preterm newborns with respiratory distress syndrome: systematic review and meta-analysis. Pediatrics. 2011; 128:e1588–e1595.

19. Ramanathan R, Bhatia JJ, Sekar K, Ernst FR. Mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant: a retrospective study. J Perinatol. 2013; 33:119–125.

20. Trembath A, Hornik CP, Clark R, Smith PB, Daniels J, Laughon M. Comparative effectiveness of surfactant preparations in premature infants. J Pediatr. 2013; 163:955–960.

21. Parry G, Tucker J, Tarnow-Mordi W. UK Neonatal Staffing Study Collaborative Group. CRIB II: an update of the clinical risk index for babies score. Lancet. 2003; 361:1789–1791.

22. Stoll BJ, Hansen NI, Bell EF, Shankaran S, Laptook AR, Walsh MC, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics. 2010; 126:443–456.

23. Moya FR, Gadzinowski J, Bancalari E, Salinas V, Kopelman B, Bancalari A, et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics. 2005; 115:1018–1029.

24. Moya F, Sinha S, Gadzinowski J, D'Agostino R, Segal R, Guardia C, et al. One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics. 2007; 119:e1361–e1370.